文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性栓塞后辅助钇-90 PET/CT引导经皮消融的预测剂量学影响的计算机模拟

Computational simulation of the predicted dosimetric impact of adjuvant yttrium-90 PET/CT-guided percutaneous ablation following radioembolization.
PubMed 文献 · EJNMMI Res · 2016-12-12

本研究为回顾性研究,纳入14例不可切除肝癌且既往接受90Y放射性栓塞的患者,基于90Y PET/CT引导模拟辅助射频消融,采用有限元法求解Pennes生物传热方程耦合Arrhenius热细胞死亡模型预测消融区。与单纯放射性栓塞相比,辅助消融后所有肿瘤吸收剂量指标均预测升高且差异有统计学意义(P<0.01),消融前肿瘤体积与D50、平均剂量、V100呈负相关(ρ<-0.5,P<0.05)。

要点

  • 模拟辅助射频消融后平均吸收剂量增加11.2±6.9 Gy,D50、D70、D90分别增加11.0±6.9 Gy、13.3±10.9 Gy、11.8±10.8 Gy。
  • V100平均增加7.2±4.2%,所有剂量指标变化均具统计学显著性(P<0.01)。
  • 消融前肿瘤体积与D50、平均剂量、V100呈负相关(ρ<-0.5,P<0.05),提示大肿瘤获益可能较小。

核心结论

  • 本研究表明,辅助90Y PET/CT引导射频消融可能改善肿瘤吸收剂量指标,这些数据可能为前瞻性临床试验提供依据。

研究设计与样本

  • 回顾性研究,纳入14例不可切除肝癌且既往接受90Y放射性栓塞的患者。
  • 采用90Y PET/CT引导模拟辅助射频消融电极放置,以有限元法求解Pennes生物传热方程并联用Arrhenius热细胞死亡模型确定三维热消融区。
  • 比较消融后肿瘤与未消融肿瘤的吸收剂量指标(平均剂量、D50、D70、D90、V100)。

主要发现

  • 与单纯放射性栓塞相比,90Y放射性栓塞联合辅助消融预测所有评估的肿瘤剂量指标均升高。
  • 平均吸收剂量增加11.2±6.9 Gy,D50增加11.0±6.9 Gy,D70增加13.3±10.9 Gy,D90增加11.8±10.8 Gy。
  • V100平均增加7.2±4.2%,所有变化均具统计学显著性(P<0.01)。
  • 消融前肿瘤体积与D50、平均剂量、V100呈负相关(ρ<-0.5,P<0.05),提示辅助射频消融对肿瘤负荷大的患者可能获益较小。

关键数值与推荐

  • D70定义为70%肿瘤的最小剂量,V100定义为接受超过100 Gy的肿瘤体积分数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 90Y PET/CT post-radioembolization imaging has demonstrated that the distribution of 90Y in a tumor can be non-uniform. Using computational modeling, we predicted the dosimetric impact of post-treatment 90Y PET/CT-guided percutaneous ablation of the portions of a tumor receiving the lowest absorbed dose. A cohort of fourteen patients with non-resectable liver cancer previously treated using 90Y radioembolization were included in this retrospective study. Each patient exhibited potentially under-treated areas of tumor following treatment based on quantitative 90Y PET/CT. 90Y PET/CT was used to guide electrode placement for simulated adjuvant radiofrequency ablation in areas of tumor receiving the lowest dose. The finite element method was used to solve Penne's bioheat transport equation, coupled with the Arrhenius thermal cell-death model to determine 3D thermal ablation zones. Tumor and unablated tumor absorbed-dose metrics (average dose, D50, D70, D90, V100) following ablation were compared, where D70 is the minimum dose to 70% of tumor and V100 is the fractional tumor volume receiving more than 100 Gy. RESULTS: Compared to radioembolization alone, 90Y radioembolization with adjuvant ablation was associated with predicted increases in all tumor dose metrics evaluated. The mean average absorbed dose increased by 11.2 ± 6.9 Gy. Increases in D50, D70, and D90 were 11.0 ± 6.9 Gy, 13.3 ± 10.9 Gy, and 11.8 ± 10.8 Gy, respectively. The mean increase in V100 was 7.2 ± 4.2%. All changes were statistically significant (P < 0.01). A negative correlation between pre-ablation tumor volume and D50, average dose, and V100 was identified (ρ < - 0.5, P < 0.05) suggesting that adjuvant radiofrequency ablation may be less beneficial to patients with large tumor burdens. CONCLUSIONS: This study has demonstrated that adjuvant 90Y PET/CT-guided radiofrequency ablation may improve tumor absorbed-dose metrics. These data may justify a prospective clinical trial to further evaluate this hybrid approach.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Pasciak AS, Lin A, Georgiades C, et al. Computational simulation of the predicted dosimetric impact of adjuvant yttrium-90 PET/CT-guided percutaneous ablation following radioembolization. EJNMMI Res. 2016. PMID: 27957721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。